Oncotelic Therapeutics, Inc. Available-for-sale Securities, Amortized Cost Basis
Oncotelic Therapeutics, Inc. (OTLC) had Available-for-sale Securities, Amortized Cost Basis of $1.11 million as of 2017-12-31, per its 10-K filed 2018-04-17.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-04-17
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $1.11M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $1.91M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $5.00M.
- 2017-03-31: Available-for-sale Securities, Amortized Cost Basis $8.34M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2017-12-31 | $1.11M 10-K · filed 2018-04-17 |
| 2017-09-30 | $1.91M 10-Q · filed 2017-11-14 |
| 2017-06-30 | $5.00M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $8.34M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $12.05M 10-K · filed 2018-04-17 |
| 2016-09-30 | $16.28M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $19.34M 10-Q · filed 2016-08-02 |
| 2016-03-31 | $22.89M 10-Q · filed 2016-05-06 |